89 related articles for article (PubMed ID: 25317804)
1. Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
Xu L; Chi C; Wang C; Zhang LM
Eur Rev Med Pharmacol Sci; 2014; 18(18):2687-92. PubMed ID: 25317804
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
6. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Beatty GL; Giantonio BJ
Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
[TBL] [Abstract][Full Text] [Related]
8. Retraction: Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
Xu L; Chi C; Wang C; Zhang LM
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):2982. PubMed ID: 25392091
[TBL] [Abstract][Full Text] [Related]
9. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.
Bunni J; Shelley-Fraser G; Stevenson K; Oltean S; Salmon A; Harper SJ; Carter JG; Bates DO
Am J Cancer Res; 2015; 5(6):2083-9. PubMed ID: 26269767
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.
Wimberger P; Gerber MJ; Pfisterer J; Erdmann K; Füssel S; Link T; du Bois A; Kommoss S; Heitz F; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Park-Simon TW; Baumann K; Hilpert F; Grube M; Schröder W; Burges A; Belau A; Hanker L; Kuhlmann JD
Clin Cancer Res; 2022 Nov; 28(21):4660-4668. PubMed ID: 36001383
[TBL] [Abstract][Full Text] [Related]
11. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.
Hegde PS; Jubb AM; Chen D; Li NF; Meng YG; Bernaards C; Elliott R; Scherer SJ; Chen DS
Clin Cancer Res; 2013 Feb; 19(4):929-37. PubMed ID: 23169435
[TBL] [Abstract][Full Text] [Related]
12. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Teknos TN; Cox C; Yoo S; Chepeha DB; Wolf GT; Bradford CR; Carey TE; Fisher SG
Head Neck; 2002 Nov; 24(11):1004-11. PubMed ID: 12410536
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
15. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
[TBL] [Abstract][Full Text] [Related]
16. The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.
Ekinci D; Kargi A; Yalcin AD; Savas B
J BUON; 2013; 18(1):245-52. PubMed ID: 23613412
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
[TBL] [Abstract][Full Text] [Related]
19. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]